COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES

摘要

A pharmaceutical composition that comprises a PDE4 inhibitor and an HMG-CoA reductase inhibitor. The PDE4 inhibitor is 2-{ 4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl} -acetamide and the HMG-CoA reductase inhibitor is atorvastatin. The composition is used for treating an inflammatory pulmonary disease, which can be asthma, COPD, sclerosis, alveolitits, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension.